Bausch Health Q3 adjusted EPS jumps 53%, beats estimates; FY outlook raised

Bausch Health Companies

28/10/2026 20:10

Overview
Pharmaceutical company's Q3 revenue rose 10% yr/yr
Adjusted EPS for Q3 rose 53% and beat analyst expectations
Company raised full-year 2026 revenue and adjusted EBITDA guidance

Outlook
Company raises 2026 full-year revenue, adjusted EBITDA and adjusted cash flow guidance
Company sees 2026 revenue at $10.975 bln to $11.175 bln, up 7%-9% from prior yr
Company expects 2026 adjusted EBITDA of $4.315 bln to $4.415 bln, up 12%-14% yr/yr

Result Drivers
SALIX SEGMENT - Growth in the Salix segment, led by Xifaxan, was the primary contributor to revenue gains
SOLTA MEDICAL ACQUISITION - Revenue growth in Solta Medical segment was driven by the acquisition of a distributor in China, though organic sales declined
DERMATOLOGY GROWTH - Double-digit growth in Dermatology contributed to gains in the Diversified segment

Company press release: ID:nPn92YzF5a

Key Details
Metric
Beat/Miss
Actual
Consensus Estimate
Q3 Adjusted EPS
Beat
$1.77
$1.29 (3 Analysts)
Q3 EPS
 
$1.15
 
Q3 Adjusted EBITDA
 
$1.31 bln
$1.05 bln (2 Analysts)
Q3 Pretax Profit
 
$597 mln
 

Analyst Coverage
The current average analyst rating on the shares is "hold" and the breakdown of recommendations is no "strong buy" or "buy", 2 "hold" and no "sell" or "strong sell"
The average consensus recommendation for the pharmaceuticals peer group is "buy."
The stock recently traded at 1 times the next 12-month earnings vs. a P/E of 1 three months ago

Reuters Recommended Reads
Oct 28 - Bausch + Lomb beats Q3 adjusted EPS estimates; raises FY outlook
Oct 28 - Biogen tops quarterly estimates on rare-disease drug strength
Oct 27 - Novartis books $2.2 billion hit from drug trial setbacks, but lifts guidance

For questions concerning the data in this report, contact Estimates.Support@lseg.com. For any other questions or feedback, contact reuters.support@thomsonreuters.com.

(This story was created using Reuters automation and AI based on LSEG and company data. It was checked and edited by a Reuters journalist prior to publication.)